Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Chin J Integr Med ; 27(6): 408-416, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33881718

RESUMEN

OBJECTIVE: To evaluate the safety and effectiveness of Qishe Pill () on neck pain in real-world clinical practice. METHODS: A multi-center, prospective, observational surveillance in 8 hospitals across Shanghai was conducted. During patients receiving 4-week Qishe Pill medication, Visual Analogue Scale (VAS) and Neck Disability Index (NDI) assessments have been used to assess their pain and function, while safety monitoring have been observed after 2 and 4 weeks. RESULTS: Results from 2,023 patients (mean age 54.5 years) suggest that the drug exposure per unit of body mass was estimated at 3.41 ± 0.62 g/kg. About 8.5% (172/2,023) of all participants experienced adverse events (AEs), while 3.8% (78/2,023) of all participants experienced adverse reaction. The most common AEs were gastrointestinal events and respiratory events. The VAS score (pain) and NDI score (function) significantly decreased after 4-week treatment. An effect-quantitative analysis was also conducted to show that the normal clinical dosage may be consider as 3-4 g/kg, at which dosage the satisfactory pain-relief effect may achieve by 40-mm reduction in VAS. CONCLUSION: These findings showed that patients with cervical radiculopathy who received Qishe Pill experienced significant improvement on pain and function. (Registration No. NCT01875562).


Asunto(s)
Vértebras Cervicales , Dolor de Cuello , China , Medicamentos Herbarios Chinos , Humanos , Persona de Mediana Edad , Dolor de Cuello/tratamiento farmacológico , Vigilancia de Productos Comercializados , Estudios Prospectivos , Resultado del Tratamiento
2.
J Mater Sci Mater Med ; 24(8): 1951-61, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23695360

RESUMEN

Implant-associated infection remains a difficult medical problem in orthopaedic surgery. Here, we report on the fabrication of gentamicin-loaded mesoporous bioactive glass (Gent-MBG) for use as a controlled antibiotic delivery system to achieve the sustained release of antibiotics in the local sites of bone defects. The high surface area and mesoporous structure of MBG enable higher drug loading efficiency (79-83 %) than non-mesoporous biological glass (NBG) (18-19 %). Gent-MBG exhibits sustained drug release for more than 6 days, and this controlled release of gentamicin significantly inhibits bacterial adhesion and prevents biofilm formation by S. aureus (ATCC25923) and S. epidermidis (ATCC35984). Biocompatibility tests with human bone marrow stromal cells (hBMSCs) indicate that MBG has better biocompatibility than NBG. Therefore, Gent-MBG can be used as a controlled drug delivery system to prevent and/or treat orthopedic peri-implant infections.


Asunto(s)
Antibacterianos/administración & dosificación , Cerámica/síntesis química , Cerámica/farmacología , Portadores de Fármacos/síntesis química , Sistemas de Liberación de Medicamentos , Gentamicinas/administración & dosificación , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/fisiología , Células Cultivadas , Cerámica/química , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos/instrumentación , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos , Gentamicinas/farmacocinética , Gentamicinas/farmacología , Humanos , Ensayo de Materiales/métodos , Pruebas de Sensibilidad Microbiana , Microtecnología/métodos , Porosidad , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/crecimiento & desarrollo
3.
Acta Pharmacol Sin ; 34(3): 393-402, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23334238

RESUMEN

AIM: To investigate whether strontium ranelate (SR), a new antiosteoporotic agent, could attenuate cartilage degeneration and subchondral bone remodeling in osteoarthritis (OA). METHODS: Medial meniscal tear (MMT) operation was performed in adult SD rats to induce OA. SR (625 or 1800 mg·kg(-1)·d(-1)) was administered via gavage for 3 or 6 weeks. After the animals were sacrificed, articular cartilage degeneration was evaluated using toluidine blue O staining, SOX9 immunohistochemistry and TUNEL assay. The changes in microarchitecture indices and tissue mineral density (TMD), chemical composition (mineral-to-collagen ratio), and intrinsic mechanical properties of the subchondral bones were measured using micro-CT scanning, confocal Raman microspectroscopy and nanoindentation testing, respectively. RESULTS: The high-dose SR significantly attenuated cartilage matrix and chondrocyte loss at 6 weeks, and decreased chondrocyte apoptosis, improved the expression of SOX9, a critical transcription factor responsible for the expression of anabolic genes type II collagen and aggrecan, at both 3 and 6 weeks. Meanwhile, the high-dose SR also significantly attenuated the subchondral bone remodeling at both 3 and 6 weeks, as shown by the improved microarchitecture indices, TMD, mineral-to-collagen ratio and intrinsic mechanical properties. In contrast, the low-dose SR did not significantly change all the detection indices of cartilage and bone at both 3 and 6 weeks. CONCLUSION: The high-dose SR treatment can reduce articular cartilage degeneration and subchondral bone remodeling in the rat MMT model of OA.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Remodelación Ósea/efectos de los fármacos , Meniscos Tibiales/efectos de los fármacos , Osteoartritis/tratamiento farmacológico , Tiofenos/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Conservadores de la Densidad Ósea/administración & dosificación , Condrocitos/efectos de los fármacos , Condrocitos/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Masculino , Meniscos Tibiales/patología , Osteoartritis/etiología , Osteoartritis/patología , Ratas , Ratas Sprague-Dawley , Factor de Transcripción SOX9/metabolismo , Espectrometría Raman , Tiofenos/administración & dosificación , Lesiones de Menisco Tibial , Factores de Tiempo
4.
J Surg Res ; 173(2): e47-52, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22261583

RESUMEN

BACKGROUND: Wear particle-induced osteolysis could lead to the aseptic loosening of implants. Studies have suggested that endotoxins, such as lipopolysaccharides (LPS), may be the primary causes of wear particle-mediated osteolysis, and that osteolysis may originate from subclinical levels of bacterial infection. However, effective therapies against wear particles and gram-negative bacterial or LPS-induced bone resorption are limited. MATERIALS AND METHODS: In the current study, the effect of berberine on LPS- and polyethylene (PE) particle-induced osteolysis in vivo was investigated using a mouse calvarial model. Osteoclast number per bone perimeter and eroded surface per bone surface were measured. RESULTS: Berberine (10 mg/kg), injected either simultaneously with LPS or 3 d after LPS (25 mg/kg) treatment, blocked LPS-induced osteoclast recruitment and bone resorption in the mouse calvarial model. A daily single-dose of berberine (10 mg/kg), injected either simultaneously with PE particles or 4 d after treatment with PE particles, blocked PE particle-induced osteoclast recruitment and bone resorption. Berberine treatment markedly decreased LPS and PE particle-induced osteoclast recruitment and bone resorption in the murine calvarial model. CONCLUSION: These results suggest that berberine may have therapeutic effect for osteolysis induced by wear particles and LPS in gram-negative bacteria.


Asunto(s)
Berberina/uso terapéutico , Osteólisis/prevención & control , Animales , Prótesis Articulares/efectos adversos , Lipopolisacáridos/efectos adversos , Masculino , Ratones , Ratones Endogámicos C57BL , Osteólisis/inducido químicamente , Fitoterapia , Polietileno/efectos adversos , Cráneo/patología
5.
J Orthop Res ; 28(4): 451-6, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19824055

RESUMEN

Diabetic patients have an increased risk of prosthesis failure requiring revision surgery. Furthermore, skeletal defects are observed in conjunction with type 1 diabetes. Using a titanium particle-induced calvarial osteolysis model in diabetic mice, we investigated the effect of diabetes on the osteolytic process and the role of naringin in its prevention. Three groups each of nondiabetic or diabetic mice were treated with vehicle only, with particles only, or with particles then naringin for 10 days. Alteration of bone indices near the midline suture were then analyzed by microcomputed tomography scanning and histology. Serum levels of osteocalcin (OCN) and cross-linked N-telopeptide of type I collagen (NTx) were measured by enzyme-linked immunosorbent assay. The decreases in new bone formation (p < 0.05), calvaria thickness (p < 0.05), bone volume (p < 0.05), midline suture area (p < 0.05), and OCN concentration (p < 0.05) found in diabetic mice were normalized with naringin treatment. Diabetic state promoted particle-induced osteolysis. Naringin, an osteoanabolic agent, improved bone indices apparently by stimulating bone formation. Therefore, naringin may be beneficial in preventing and treating debris-mediated periprosthetic osteolysis after total joint replacement, especially in diabetics.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Flavanonas/farmacología , Curación de Fractura/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Osteólisis/prevención & control , Cráneo/efectos de los fármacos , Animales , Sustitutos de Huesos/química , Colágeno Tipo I/sangre , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/fisiopatología , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/fisiopatología , Medicamentos Herbarios Chinos , Curación de Fractura/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Osteocalcina/sangre , Osteogénesis/fisiología , Osteólisis/sangre , Osteólisis/complicaciones , Péptidos/sangre , Fitoterapia , Extractos Vegetales/farmacología , Polypodiaceae/química , Cráneo/patología , Titanio/química , Tomografía Computarizada por Rayos X
6.
Int J Antimicrob Agents ; 34(1): 60-6, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19157797

RESUMEN

Staphylococcus epidermidis is one of the main causes of medical device-related infections owing to its adhesion and biofilm-forming abilities on biomaterial surfaces. Berberine is an isoquinoline-type alkaloid isolated from Coptidis rhizoma (huang lian in Chinese) and other herbs with many activities against various disorders. Although the inhibitory effects of berberine on planktonic bacteria have been investigated in a few studies, the capacity of berberine to inhibit biofilm formation has not been reported to date. In this study, we observed that berberine is bacteriostatic for S. epidermidis and that sub-minimal inhibitory concentrations of berberine blocked the formation of S.epidermidis biofilm. Using viability assays and berberine uptake testing, berberine at a concentration of 15-30mug/mL was shown to inhibit bacterial metabolism. Data from this study also indicated that modest concentrations of berberine (30-45mug/mL) were sufficient to exhibit an antibacterial effect and to inhibit biofilm formation significantly, as shown by the tissue culture plate (TCP) method, confocal laser scanning microscopy and scanning electron microscopy for both S. epidermidis ATCC 35984 and a clinical isolate strain SE243. Although the mechanisms of bacterial killing and inhibition of biofilm formation are not fully understood, data from this investigation indicated a potential application for berberine as an adjuvant therapeutic agent for the prevention of biofilm-related infections.


Asunto(s)
Antibacterianos/farmacología , Berberina/farmacología , Biopelículas/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Staphylococcus epidermidis/efectos de los fármacos , Staphylococcus epidermidis/fisiología , Berberina/aislamiento & purificación , China , Humanos , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana , Plantas Medicinales/química
7.
Zhong Xi Yi Jie He Xue Bao ; 2(3): 208-9, 2004 May.
Artículo en Chino | MEDLINE | ID: mdl-15339447

RESUMEN

OBJECTIVE: To study the effect of melittin on apoptsis and necrosis of osteosarcoma cell line U2 OS in vitro. METHODS: Osteosarcoma cell line U2 OS was treated with melittin. The growth and proliferation was observed by MTT assay and cell counting, and the necrosis was estimated by Trypan blue staining. The cell apoptsis, Fas and Apo2. 7 expression were detected by cytometer. RESULTS: The data showed that melittin could inhibit the proliferation of U2 OS dose-dependently at 16 and 64 mg/L. Cell apoptsis was detected by cytometer, when the cells were treated by 16 mg/L and 32 mg/L of melittin respectively, and the percentages of Fas and Apo2. 7 positive cells were increased. CONCLUSION: Melittin inhibits the proliferation of osterosarcoma cell line through up-regulating Fas expression and inducing apoptsis.


Asunto(s)
Apoptosis/efectos de los fármacos , Meliteno/toxicidad , Animales , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Citometría de Flujo , Concentración 50 Inhibidora , Osteonecrosis/inducido químicamente , Osteonecrosis/metabolismo , Osteosarcoma/metabolismo , Osteosarcoma/patología , Proteínas Proto-Oncogénicas/análisis , Proteínas Proto-Oncogénicas/efectos de los fármacos , Proteínas Proto-Oncogénicas/metabolismo , Receptores del Factor de Necrosis Tumoral/análisis , Receptores del Factor de Necrosis Tumoral/efectos de los fármacos , Receptores del Factor de Necrosis Tumoral/metabolismo , Receptor fas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA